drugset / Trial / NCT02252354
TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this 2 part study is to look at how TAK-385 is taken up, broken down and removed from the body when given as a radiolabelled oral solution (by mouth) or as an oral tablet (by mouth) followed by a radiolabelled intravenous (IV) infusion (into the arm vein).
Timeline
- Start
- 2014-09
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relugolix | Small molecule | 80 ug | Oral |
| Subject | Relugolix | Small molecule | 80 mg | Oral |
Indications
No indication recorded.